Berlin, Germany
1-4 June

Join us for the

European Society of Human Genetics Conference 2024!

Asuragen, a Bio-Techne brand’s unique and proprietary AmplideX® and QuantideX® chemistries power simple and streamlined solutions for analysis of complex genomic targets.

Visit us at stand #516

Equitable Genetic Coverage

We are committed to advancing equitable healthcare by offering comprehensive genetic coverage. Our extensive range of genetic tests and services ensures patients receive accurate diagnoses, personalized treatment plans, and improved outcomes.

Innovative Approaches to Cancer Monitoring

We are proud to share our innovative approaches to cancer monitoring and management. Through state-of-the-art technologies and groundbreaking research, we strive to revolutionize cancer care by early detection, targeted therapies, and effective management strategies.

Asuragen Corporate Satellite

Meeting Room New York 1
Sunday 2 June, 12:00-13:00 CEST

Unravelling Complexity Through Innovation: Combining AmplideX PCR Chemistries and Nanopore Sequencing for Robust Variant Characterisation in 11 Hard-to-Decipher Genes

Striving for Simplicity: Prototype Assay Performance with a Panel of 11 Challenging Genes Using Nanopore Sequencing and AmplideX Chemistry


Dr. John Milligan

R&D Director, Asuragen, a Bio-Techne brand

Evaluation of a Streamlined Nanopore Sequencing Workflow for Rare Variant Characterisation in a Laboratory Setting

Prof. Anne-Sophie Lebre

Professor at the University of Reims

Champagne-Ardenne, Consultant Reims University Hospital

Find out more about ESHG

Learn More
Back To